These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27591793)

  • 1. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 Jun; 79(108):32464-81. PubMed ID: 24908687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
    Kesselheim AS; Rome BN; Sarpatwari A; Avorn J
    Health Aff (Millwood); 2017 Feb; 36(2):362-370. PubMed ID: 28100464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
    Kwok M; Foster T; Steinberg M
    Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging Novel and Existing Pathways to Approve New Therapeutics to Treat Serious Drug-Resistant Infections.
    Hwang TJ; Kesselheim AS
    Am J Law Med; 2016 May; 42(2-3):429-450. PubMed ID: 29086648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the GAIN Act a turning point in new antibiotic discovery?
    Brown ED
    Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis.
    Rome BN; Kesselheim AS
    Clin Infect Dis; 2020 Oct; 71(7):1671-1675. PubMed ID: 31630159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprioritizing Research Activity for the Post-Antibiotic Era: Ethical, Legal, and Social Considerations.
    Hey SP; Kesselheim AS
    Hastings Cent Rep; 2017 Mar; 47(2):16-20. PubMed ID: 28301705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic bill doesn't GAIN enough ground.
    Ambrose PG
    Nat Med; 2011 Jul; 17(7):772. PubMed ID: 21738147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
    Mostaghim SR; Gagne JJ; Kesselheim AS
    BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
    [No Abstract]   [Full Text] [Related]  

  • 18. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.
    Kesselheim AS
    Milbank Q; 2011 Sep; 89(3):450-502. PubMed ID: 21933276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cheat sheet to navigate the complex maze of exclusivities in the United States.
    Peng B; Tomas MC
    Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306
    [No Abstract]   [Full Text] [Related]  

  • 20. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.
    Outterson K; Powers JH; Seoane-Vazquez E; Rodriguez-Monguio R; Kesselheim AS
    J Law Med Ethics; 2013; 41(3):688-96. PubMed ID: 24088160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.